Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DarioHealth (DRIO) Research & Development (2016 - 2025)

DarioHealth filings provide 13 years of Research & Development readings, the most recent being $2.6 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 50.12% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.8 million, a 42.96% decrease, with the full-year FY2025 number at $13.8 million, down 42.96% from a year prior.
  • Research & Development hit $2.6 million in Q4 2025 for DarioHealth, down from $3.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.8 million in Q2 2024 to a low of $2.6 million in Q4 2025.
  • Median Research & Development over the past 5 years was $5.0 million (2022), compared with a mean of $4.8 million.
  • Biggest five-year swings in Research & Development: surged 477.15% in 2021 and later tumbled 50.12% in 2025.
  • DarioHealth's Research & Development stood at $5.3 million in 2021, then dropped by 10.05% to $4.8 million in 2022, then fell by 12.25% to $4.2 million in 2023, then rose by 25.86% to $5.3 million in 2024, then tumbled by 50.12% to $2.6 million in 2025.
  • The last three reported values for Research & Development were $2.6 million (Q4 2025), $3.3 million (Q3 2025), and $3.7 million (Q2 2025) per Business Quant data.